Authors Posts by Head Editor

Head Editor

5140 POSTS 18 COMMENTS

0 399

Endexx Begins Shipment of Third Eye Chai CBD-Infused Gourmet Tea Beverages

Endexx’s first product launch Third Eye Chai™, a masala chai tea, was a result of its license and distribution deal with The Mad Hatter Coffee & Tea Co. The collaboration offers a major opportunity to bring specific hemp and CBD-infused natural blends to the global health and whole foods markets, a major step for the cross-over markets valued at over $3 billion.

Todd Davis, CEO of Endexx, stated, “Our CBD-infused Chai, is primarily a wellness product that contains only the finest tea and herb ingredients and provides our customers with an enhanced tea experience. Although there is still a lot of education to be done on the health benefits of CBD, it has been proven to alleviate inflammation, muscle spasms, anxiety, epileptic seizures, and pain. Our licensing and partnership agreement with The Mad Hatter Coffee & Tea Co., will initially allow us to distribute our tea in the US, following with global distribution. This first product launch enables Endexx to generate licensing agreements with several large family owned conglomerates and distributors that have expressed strong interest in licensing our products, providing for additional revenue opportunities.”

About Endexx
Endexx provides innovative inventory management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and an “End of Sale” technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com, www.m3hub.com.

Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3130797

0 281

Green Cures & Botanical Distribution, Inc. Announces Strategic Partnership with Elev8 Brands, Inc. for Premium Coffee Brand

Green Cures and Botanical Distribution, Inc. selected Elev8 Brands, Inc. as their partner to launch an exclusive blend of specialty coffee under the Hollywood Hills™ brand. Their prominent manufacturer has an Amazon.com approved facility that is BRC (British Retail Consortium) and Fair Trade-Certified sourced with organically-grown coffee beans.

According to the Specialty Coffee Association of America, the retail value of the U.S. coffee market is estimated to be $48 billion dollars with the specialty market comprising approximately 55% of this figure. The Business Insider states that “coffee is more than popular: it’s ubiquitous. No other beverage is as revered or respected.”

Chief Operating Officer Michael Lajtay stated, “Our new all-natural, organic line of Hollywood Hills™ coffee will feature multiple flavors including a proprietary extra-strength formula that delivers an added caffeine boost coffee fans will enjoy world-wide. We are proud to announce that Hollywood Hills™ products adhere to the highest Fair-Trade certifications and quality standards which are requirements for large retail customers where we intend to have the Hollywood Hills™ brand on the shelves of.”

With the launch of Hollywood Hills™ coffee the companies are in discussions to develop a hemp-derived, cannabidiol (CBD) infused brand of Hollywood Hills™ coffee that will combine the health benefits of hemp-derived extracts with the extra-strength proprietary coffee blend.

“We are thrilled to launch the Hollywood Hills™ coffee brand line that will consist of an array of flavorful and uniquely caffeinated coffees. As we reach regional and national distribution we are excited to pursue launches of hemp-based coffees where there are little or no competitors and enormous potential for growth,” concluded Lajtay.

About Green Cures& Botanical Distribution, Inc. ( OTC PINK : GRCU )
Green Cures & Botanical Distribution Inc., is revenue-generating company that wholesales and retails hemp-infused nutritional, botanical, sports, and body care products. The company is currently Web-based and focuses on online retailing. Green Cures & Botanical Distribution Inc., operates a diverse portfolio of products and services within the botanical and cannabis industry, as permitted by law. From concept to production and distribution, Green Cures & Botanical Distribution Inc., is continuously creating and introducing products that promote a healthy life style. For more information visit: http://www.originalhollywoodhemp.com/.

About Elev8 Hemp LLC
Elev8 Hemp LLC is a wholly-owned subsidiary of Elev8 Brands, Inc. which focuses on the development and marketing of hemp-based food, beverage, and health care products including hemp coffee, hemp water, and hemp-based skin care products.

Please visit www.elev8hemp.com for more information

Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

0 335

Canabo Opens Clinic in Kelowna, BC and Provides Update on Peak Medical Group

Canabo is also pleased to provide an update on its growth with Peak Medical Group (“Peak Medical”) who operates partner clinics for Canabo throughout Alberta. Peak Medical has recently opened a new, second location in Edmonton in order to accommodate high patient demand.

Dr. Neil Smith, Executive Chairman stated, “Kelowna marks the 6th clinic opening for Canabo in 2017 and demonstrates we are continuing to execute on our aggressive clinic roll out schedule. We are also pleased with our patient growth in Alberta through our partner Peak Medical.”

About Canabo Medical Inc.

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo has 16 clinics across Canada with several additional locations set to open in 2017.

Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions that may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

0 1563

$VPRB LP Announces 2016 Fourth Quarter and Full Year Results

VPR Brands, LP (OTC PINK: VPRB) released 2016 fourth quarter and full year revenue and financials. 2016 revenue totaled $1,580,676, which represents a 4,620.85% increase over 2015 revenue of $342. , For 2016, VPR Brands had a gross profit margin of 30.42%, gross profit of $480,852 and a net operating loss of $327,757.

Fourth quarter 2016 revenue totaled $972,322, representing a 59.82% increase over third quarter 2016 revenue of $608,354. Fourth quarter 2016 operating margins were down slightly compared to the third quarter 2016 to 29.03%, with $282,298 in gross profit and a net operating loss of $206,174.


Click Here Now To Read Full PR


$VPRB Annual Financial Statement – 10K Filing

VPR Brands, LP (VPRB) Files Annual Financial Statement (10K) After Market Close On Monday 4-17-2017


Click Here Now To Read Filing


Industrial Hemp Could Take Off In New York State

The recently passed state budget eliminates a cap on New York’s prospering industrial hemp industry. That will allow more farmers to be able to research, grow, and process a crop that could turn into a million dollar business. The industrial hemp industry’s first hurdle is also the biggest misconception most people have about.


Click Here Now To Read Full Article


Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. We may buy or sell additional shares of (VPRB) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1687
VPR Brands

 VPR Brands, LP (OTC PINK: VPRB) released 2016 fourth quarter and full year revenue and financials. 2016 revenue totaled $1,580,676, which represents a 4,620.85% increase over 2015 revenue of $342. , For 2016, VPR Brands had a gross profit margin of 30.42%, gross profit of $480,852 and a net operating loss of $327,757.

Fourth quarter 2016 revenue totaled $972,322, representing a 59.82% increase over third quarter 2016 revenue of $608,354. Fourth quarter 2016 operating margins were down slightly compared to the third quarter 2016 to 29.03%, with $282,298 in gross profit and a net operating loss of $206,174.

“The acquisition we made in 2016 was a bold move that has added incremental business and value to the Company for the last half of 2016 and has given us a running start into 2017. We believe that the Company is now well positioned to take advantage of the growing cannabis market segment,” said Kevin Frija, CEO of VPR Brands, LP. “We will continue to stay focused on our mission of building long-term value for the Company, both organically or through additional acquisitions that make sense for the Company.”

“I couldn’t be more excited for our portfolio of brands, our team of people, our great clients, our strategic alliances and our growth potential within the rapidly expanding cannabis space. Although 2016 was a short year for us, I believe we have set a solid foundation for growth that we can build upon for years to come,” commented Daniel Hoff, COO of VPR Brands, LP.

Although our sales are not segregated by brand or product category, our primary revenue source is from vaporization devices specifically created for use with medical cannabis and recreational marijuana. These devices are specifically created for use with extract oils and concentrates which are vaped, providing optimal results and the best experience for patients and recreational users. Vaporizers are far more convenient and discrete compared to traditional cannabis use methods. These units are compact, easy to carry and concealable. Modern cannabis vaporizers do not emit distinct and lingering odors that are affiliated with traditional marijuana use. We believe that portable vaporizers as the fastest growing delivery mechanism for marijuana. Our team is currently working with other market leaders within cannabis growth and extraction to innovate and further educate the marketplace on its advantages.

About VPR Brands LP:

VPR Brands is a technology company whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The Company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the Company on the web at www.vprbrands.com.

Forward-Looking Statements: 
This news release contains statements that involve expectations, plans or intentions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contact Information: 

VPR Brands, LP 

Kevin Frija CEO 

(954) 715-7001 

info@vprbrands.com

0 484

Lexaria Welcomes Canada’s Proposed Cannabis Legislation

The Cannabis Act provides the opportunity for Canada to craft the safest and most responsible cannabis production and consumption framework in the world, especially with respect to consistent and reliable dosing formats that technology such as Lexaria’s enables in modern edible formats. The Cannabis Act prohibits second hand smoke and second hand vapours from inhaled cannabis use, consistent with existing federal legislation that prohibits second hand cigarette smoke. It is also in everyone’s best interest to support the consumer shift away from the high sugar, high fat, inconsistent and unpredictable effectiveness and onset-times associated with edible product formats endemic in other adult-use cannabis markets.

Lexaria’s patented technology — currently subject to collaborative examination together with Canada’s National Research Council — is strongly supportive of macro trends by embracing edible cannabis formats with zero added sugar, and lower micro-dosage unit sizes. Micro dosing of 10mg and even as little as 5mg of THC is rapidly gaining popularity in other legal cannabis jurisdictions that mandate micro dosing edible formats as a more responsible way of consuming cannabis, without creating issues of second hand smoke or second hand vapour for non-consumers. Micro dosing tends to lead to lower overall levels of consumption with reduced likelihood of overconsumption.

“Modern technology allows for safer, more consistent and less obtrusive methods of cannabis use than ever before,” says Chris Bunka, CEO of Lexaria. “We have a once in a lifetime opportunity to support consumer health trends in the cannabis world through advanced delivery techniques unlike anything available even five years ago. I hope to see Canada lead the world in embracing public health in the cannabis sector.”

While utilizing Lexaria’s technology, both in vitro and human biomarker studies point to significantly higher cannabinoid absorption and quicker & and more consistent onset of effects than can be achieved with conventional edible preparations. Further consumer focus studies conducted by Lexaria licensees have reported a more pleasurable, faster acting and predictable experience.

Through a patented process that combines cannabinoids with natural delivery enhancers at a molecular level, Lexaria’s technology is believed to alter the absorption pathway of cannabinoids within the human body (designed to bypass first-pass liver filtration when desired for more rapid onset of effectiveness). More efficient and effective absorption of cannabinoids has been shown, while simultaneously masking and even eliminating inherent strong flavours and odors typical of cannabis extracts, avoiding the need for added sugar and fat. Lexaria’s technology was conceived to allow for the creation of edible product formats that mirror as closely as possible the potency and onset of effectiveness associated with inhalational dosing without its unwanted effects. Lexaria is thrilled to have the opportunity to lead advancements in bio-availability and speed & predictability of onset for health-conscious consumers.

About Lexaria

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

0 619
Marijuana Stocks

The cannabis train has left the station and this has left states searching for solutions to best capitalize on this emerging opportunity.

Last week, Michigan announced the creation of an agency to centralize all aspects of cannabis industry in the state. The agency dubbed the Bureau of Medical Marijuana Regulation believes that a centralized service will streamline cannabis regulations and allow businesses to operate more efficiently.

This development is exciting as it represents a significant change in the way cannabis is regulated by states. We expect this program to be closely watched by other states and its progression will something to keep an eye on.

LARA Director Shelly Edgerton said, “BMMR’s organizational structure puts Michigan at the forefront of state medical marijuana regulation. Many other states have various licenses and patient programs spread throughout different departments and agencies.”

Cannabis Support at All-Time Highs

Cannabis support in the United States has grown significantly over the last two years and we are reaching a tipping point. Despite the increased support, concerns among cannabis supporters have increased following recent commentary from the newly appointed Attorney General Jeff Sessions.

March data from the General Social Survey showed growing support for legal cannabis in the United States. The number of Americans who think cannabis use should be legal increased to 57% from 52% in 2014.

Another interesting finding from this data pertains to the growing number of people (70%) against the federal government’s enforcement of prohibition laws in states that have legalized cannabis.

0 1301

The recently passed state budget eliminates a cap on New York’s prospering industrial hemp industry. That will allow more farmers to be able to research, grow, and process a crop that could turn into a million dollar business. The industrial hemp industry’s first hurdle is also the biggest misconception most people have about.

SUNY Morrisville Researcher Jennifer Gilbert Jenkins stated, “It is related to marijuana is what most people think. But industrial hemp does not have any THC in it.” It’s THC that creates the marijuana plant’s high. However, the biological connection between marijuana and hemp continues to create a roadblock for growing a crop that farmers cultivated in New York state more than a century ago.

So while there are still major Drug Enforcement Administration regulations in place regarding acquiring seed and transporting industrial hemp, the New York’s loosening of rules around the industry opens up farmers to a crop that has earnings potential. Processed hemp is already sold locally, valued for its high protein content. Jenkins stated, “You can walk into your Wegmans and buy a bag of hemp seeds just like you can buy a bag of sunflower seeds. You can buy hemp oil, you can buy hemp meal to use in shakes and smoothies.”

However, most of the hemp products sold in New York right now come from Canada and China. Jenkins, who’s researching the best ways to fertilize hemp in the field, says New York isn’t the only state that sees potential in industrial hemp. That may be spurring New York state to move quickly. Jenkins said, “The state who get the grows happening faster are going to benefit more.” They’re going to be out ahead.” New York state will be holding a hemp summit later this year in the Southern Tier to highlight the challenges and opportunities to grow the industry.

0 477

Today’s Research Reports on Biotech Stocks to Watch: Cara Therapeutics and Incyte

RDI Initiates Coverage on:

Cara Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=CARA

Incyte Corporation
https://ub.rdinvesting.com/news/?ticker=INCY

Cara Therapeutics’ shares declined 2.97 percent to close at $17.01 a share on Monday. The stock traded between $16.76 and $17.90 on volume of 2.02 million shares traded. Cara’s most advanced compound, CR845, is currently undergoing clinical testing for acute pain, chronic pain and uremic pruritus (itch). On March 28th, the company announced positive top-line results from Part A of its Phase 2/3 trial of I.V. CR845 in patients with uremic pruritus (UP). Shares of Cara Therapeutics have gained approximately 83.1 percent year-to-date.

“We are extremely pleased with these results, where I.V. CR845 demonstrated sustained clinical and quality of life benefits in dialysis patients suffering from UP and supports the viability of this therapeutic approach for the long-term treatment of this unmet medical need,” said Derek Chalmers, Ph.D., D.Sc., President and CEO of Cara Therapeutics. “As a next step, we plan to meet with the FDA to finalize the trial design of Part B of this Phase 2/3 study and to initiate patient recruitment later this year.”

Access RDI’s Cara Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=CARA

Incyte’s shares dropped 10.49 percent to close at $126.07 a share on Monday. The stock traded between $124.05 and $127.43 on volume of 6.92 million shares traded. The company and Eli Lily announced that the FDA did not approve the New Drug Application (NDA) for baricitinib, a treatment for moderate-to-severe rheumatoid arthritis. The FDA has requested additional clinical data to determine the most appropriate doses. Shares of Incyte have gained approximately 25.73 percent year-to-date.

“We are disappointed with this action. We remain confident in the benefit/risk of baricitinib as a new treatment option for adults with moderate-to-severe RA,” said Christi Shaw, President of Lilly Bio-Medicines. “We will continue to work with the FDA to determine a path forward and ultimately bring baricitinib to patients in the U.S.”

Access RDI’s Incyte Research Report at:
https://ub.rdinvesting.com/news/?ticker=INCY

Our Actionable Research on Cara Therapeutics Inc. (NASDAQ: CARA) and Incyte Corporation (NASDAQ: INCY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

0 864
VPR Brands

VPR Brands, LP (VPRB) Files Annual Financial Statement (10K) After Market Close On Monday 4-17-2017

Click Here: VPRB10K For Full 10K Filing

About VPR Brands LP:

VPR Brands is a technology company; whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the company on the web at www.vprbrands.com.


Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. We may buy or sell additional shares of (VPRB) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements